Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
16714-0927-01 16714-0927 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 8, 2019 In Use
43817-0906-01 43817-0906 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Subcutaneous May 6, 2019 In Use
71288-0153-95 71288-0153 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Nov. 2, 2020 In Use
72606-0558-01 72606-0558 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Jan. 6, 2020 In Use
71288-0115-30 71288-0115 Azacitidine Azacitidine 100.0 mg/30mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Nov. 2, 2020 In Use
00591-2897-49 00591-2897 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 22, 2016 April 30, 2019 No Longer Used
16714-0777-01 16714-0777 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 4, 2018 June 10, 2020 In Use
63759-0003-01 63759-0003 azacitidine for Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Dec. 5, 2016 In Use
68001-0527-54 68001-0527 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb. 15, 2022 In Use
43598-0143-62 43598-0143 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous April 20, 2022 In Use
67457-0254-30 67457-0254 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 23, 2016 In Use
16714-0578-01 16714-0578 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Nov. 18, 2022 In Use
00781-3253-94 00781-3253 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 16, 2013 Feb. 28, 2025 In Use
51991-0797-98 51991-0797 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Subcutaneous Aug. 7, 2017 Jan. 31, 2024 In Use
00781-9253-94 00781-9253 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 27, 2014 Sept. 30, 2024 In Use
60505-6271-01 60505-6271 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Oct. 11, 2023 In Use
68001-0504-54 68001-0504 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous June 11, 2021 In Use
69097-0805-40 69097-0805 Azacitidine Azacitidine For 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 26, 2019 In Use
71258-0015-02 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
71258-0015-22 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
59676-0040-28 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0040-56 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0050-28 59676-0050 Erdafitinib BALVERSA 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-56 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-84 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
42367-0521-25 42367-0521 Bendamustine Hydrochloride BELRAPZO 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 3, 2019 In Use
42367-0520-25 42367-0520 bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 15, 2018 Sept. 30, 2020 No Longer Used
10019-0079-01 10019-0079 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 15, 2022 In Use
55150-0392-01 55150-0392 BENDAMUSTINE HYDROCHLORIDE BENDAMUSTINE HYDROCHLORIDE 100.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 5, 2023 In Use
55150-0391-01 55150-0391 BENDAMUSTINE HYDROCHLORIDE BENDAMUSTINE HYDROCHLORIDE 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 5, 2023 In Use
73536-0500-01 73536-0500 ROPEGINTERFERON ALFA-2B BESREMi 500.0 ug/mL Immunotherapy Cytokine Interferon Subcutaneous Nov. 12, 2021 In Use
00409-1703-01 00409-1703 BORTEZOMIB BORTEZOMIB 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
00409-1704-01 00409-1704 BORTEZOMIB BORTEZOMIB 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
10019-0991-01 10019-0991 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
25021-0244-10 25021-0244 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2022 In Use
55150-0337-01 55150-0337 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
60505-6050-04 60505-6050 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
70710-1411-01 70710-1411 BORTEZOMIB BORTEZOMIB 1.0 mg/mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
70771-1708-01 70771-1708 BORTEZOMIB BORTEZOMIB 1.0 mg/mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
00069-0193-01 00069-0193 Bosutinib monohydrate BOSULIF 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 18, 2017 In Use
70255-0025-01 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral June 27, 2018 In Use
70255-0025-03 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral June 27, 2018 In Use
70255-0025-05 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral Aug. 3, 2020 In Use
70255-0025-06 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral Aug. 3, 2020 In Use
70255-0020-01 70255-0020 Encorafenib BRAFTOVI 50.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral June 27, 2018 March 13, 2019 In Use
73153-0900-01 73153-0900 Lisocabtagene maraleucel BREYANZI Immunotherapy CAR-T CD19 Feb. 5, 2021 In Use
72579-0011-01 72579-0011 Zanubrutinib BRUKINSA 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Nov. 14, 2019 Sept. 30, 2021 In Use
72579-0011-02 72579-0011 Zanubrutinib BRUKINSA 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Nov. 14, 2019 In Use
62756-0452-36 62756-0452 Octreotide acetate BYNFEZIA Pen 2.5 mg/mL Hormonal Therapy Somatostatin Analog Subcutaneous April 29, 2020 In Use
62756-0452-37 62756-0452 Octreotide acetate BYNFEZIA Pen 2.5 mg/mL Hormonal Therapy Somatostatin Analog Subcutaneous April 29, 2020 In Use

Found 10,000 results in 4 milliseconds — Export these results